Pharmaceutical Technology

JANUARY 17, 2023

Bimagrumab is an activin receptor type 2B (ACVR2B or EC 2.7.11.30) antagonist that offers a unique mechanism of action within the obesity market. Despite its high price tag, bimagrumab’s unique features set it apart from currently marketed therapies. Mounjaro is anticipated to launch in the US later this year or by early 2024.

Development 130

Development Compliance Trials Marketing 130

XTalks

NOVEMBER 24, 2022

Related: Roctavian, the First Hemophilia A Gene Therapy, Attains EC Approval. While the price tag of Hemgenix is quite steep, CSL Behring told Fierce Pharma that the cost of treating patients with moderate to severe hemophilia to healthcare systems is more than $20 million over their lifetimes.

Gene Therapy 52

Gene Therapy Gene FDA Approval Genetics 52

Pharmaceutical Technology

JUNE 21, 2023

The high price tag may be hard to defend , but with lifetime treatment costs for haemophilia B reaching as high as $23m for some, the single-dose treatment could prove far more cost-effective. Despite the limited market, the price tags of haemophilia make it potentially lucrative. Haemophilia B is a rare condition.

Gene Therapy 246

Gene Therapy Gene Protein Sales 246

The Pharma Data

MAY 4, 2021

In February 2021, Pfizer and BioNTech announced an agreement with the European Commission (EC) to supply an additional 200 million doses of BNT162b2 to the 27 EU member states. A decision from the EC is expected in 2022. In addition, the companies have since requested similar amendments by other regulatory authorities worldwide.

Vaccination 40

Vaccination Vaccine Production Sales 40